-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of the State Food and Drug Administration showed that Liaoning Haisco Pharmaceutical's Palonosetron Hydrochloride Injection was approved as a supplementary application.
In February of this year, Liaoning Haisco Pharmaceutical had already passed a product regulation
.
According to data from Meinenet, the sales of Palonosetron Hydrochloride Injection in China's public medical institutions in 2020 will exceed 1.
September 09, 2021, release of drug approval documents pending receipt
Data show that Palonosetron Hydrochloride Injection is a second-generation long-acting 5-HT3 receptor antagonist.
Compared with similar drugs such as ondansetron and granisetron, Palonosetron has a smaller dosage.
The advantages of high plasma protein binding rate and long half-life are superior to traditional 5-HT3 receptor antagonists for acute CINV (chemotherapy-related nausea and vomiting) and delayed CINV, especially for delayed CINV
.
Sales of Palonosetron Hydrochloride Injection in China's Public Medical Institutions in Recent Years (Unit: 100 million yuan)
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
Palonosetron Hydrochloride Injection was developed by Helsinn Healthcare SA and was approved for marketing in China in 2018
.
According to data from Minai.
There are 14 manufacturers of Palonosetron Hydrochloride Injection.
Among them, Qilu Pharmaceutical (Hainan) has the largest market share, accounting for nearly 50%, and Hangzhou Jiuyuan Gene and Zhengda Tianqing Pharmaceutical Group have market shares exceeding 10%.
.
At present, the product has been reviewed by 7 companies.
It is worth mentioning that Palonosetron Hydrochloride Injection is the fifth batch of collected varieties, Qilu Pharmaceutical (Hainan), Yangzijiang Pharmaceutical Group Sichuan Hairong Pharmaceutical, Jiangsu Hengrui Pharmaceutical, Liaoning Haisco Pharmaceutical, Jiangsu Osay Kang Pharmaceutical and Hangzhou Jiuyuan Gene won the bid, and the market structure of this product may change in the future
Source: official website of the State Food and Drug Administration, Mi Nei.
